Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | ICMT | O60725 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21423075 | 0.93 | MEN1 (0.41) | NR1I2MEN1KMT2ASMN1; SMN2KCNH2 | |
| SCHEMBL22639542 | 0.85 | TAS1R3 (0.36) | SMN1; SMN2KCNH2 | |
| SCHEMBL18671786 | 0.83 | NR1I2 (0.36) | NR1I2MEN1KMT2ASMN1; SMN2KCNH2 | |
| SCHEMBL18671760 | 0.83 | NR1I2 (0.36) | NR1I2MEN1KMT2ASMN1; SMN2KCNH2 | |
| SCHEMBL8487906 | 0.81 | KCNH2 (0.36) | NR1I2MEN1KMT2ASMN1; SMN2KCNH2 | |
| SCHEMBL24351028 | 0.81 | NR1I2 (0.42) | NR1I2MEN1KMT2ASMN1; SMN2PRSS1 | |
| SCHEMBL21725468 | 0.81 | NR1I2 (0.42) | NR1I2MEN1KMT2ASMN1; SMN2PRSS1 | |
| SCHEMBL18866561 | 0.80 | CES2 (0.38) | SMN1; SMN2 | |
| SCHEMBL26326734 | 0.80 | CSNK1E (0.41) | MEN1KMT2ASMN1; SMN2KCNH2CSNK1E | |
| SCHEMBL23564615 | 0.80 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2KCNH2CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361925-A1 | INHIBITORS OF BETA-HYDROXYLASE FOR TREATMENT OF CANCER | RHODE ISLAND HOSPITAL (US) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361925-A1 | INHIBITORS OF BETA-HYDROXYLASE FOR TREATMENT OF CANCER | ASPH, CYP46A1, ALDH7A1 | NR1I2 172/4885MEN1 4462/4885KMT2A 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.